Company Filing History:
1 out of 987 
1 out of 1,210 
Years Active: 2017
Title: Kehmia Titanji: Innovator in Cancer and Infection Treatment
Introduction
Kehmia Titanji is a notable inventor based in Atlanta, GA, who has made significant contributions to the field of medical science. His work primarily focuses on developing methods for treating infections and tumors through innovative approaches involving PD-1 antagonists. With one patent to his name, Titanji's research has the potential to enhance immune responses in patients suffering from persistent infections and tumors.
Latest Patents
Titanji's patent, titled "Methods for the treatment of infections and tumors," discloses the use of PD-1 antagonists to reduce the expression or activity of PD-1 in subjects. This groundbreaking method can enhance immune responses specific to infectious agents or tumor cells. The patent outlines that subjects with infections, such as persistent infections, can be treated using these PD-1 antagonists. Furthermore, patients with tumors can also benefit from this treatment. The patent includes methods for transplanting activated T cells that recognize specific antigens and administering a therapeutically effective amount of a PD-1 antagonist. Additionally, it describes methods for determining the efficacy of the PD-1 antagonist in treated subjects.
Career Highlights
Kehmia Titanji has worked with prestigious institutions, including Emory University and Dana-Farber Cancer Institute. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer and infection treatment.
Collaborations
Titanji has collaborated with notable colleagues, including Rafi Ahmed and Rama Rao Amara. Their combined expertise has furthered research in immunology and therapeutic strategies.
Conclusion
Kehmia Titanji's innovative work in the treatment of infections and tumors through PD-1 antagonists showcases his dedication to advancing medical science. His contributions have the potential to improve patient outcomes and enhance the understanding of immune responses.